The Florida Society of Clinical Oncology is pleased to announce the 2025 Fall Congress, a premier two-day event designed to elevate the practice of oncology through evidence-based education and clinical collaboration. This comprehensive conference will feature five specialized educational tracks: Multidisciplinary, Pharmacy, Advanced Practice Providers (APP), Nurse/Navigator, and Administrator, providing a platform for professionals across all oncology disciplines to engage in the latest scientific advancements and clinical practices.
The congress will focus on the most current trends in oncology care, integrating cutting-edge research with practical applications aimed at improving patient outcomes. Attendees will have the opportunity to participate in presentations from renowned experts, offering insights into innovative therapies, multidisciplinary approaches, and emerging treatment paradigms. These sessions will foster dynamic discussions on optimizing clinical workflows, enhancing patient care strategies, and addressing complex challenges in oncology.
Continuing education credits will be provided for all participants, ensuring the advancement of professional competencies in the evolving field of oncology. Additionally, FLASCO members can attend the congress at no cost with an active membership, granting exclusive access to this essential gathering of leaders in oncology.
Save the Date
Announcement
Agenda
Hotel
Book Your Room
Signia by Hilton, Orlando Bonnet Creek
14100 Bonnet Creek Resort Ln, Orlando, FL 32821
Posters
Posters
- Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in c-Met Protein–Overexpressing NSCLC: LUMINOSITY Study [AbbVie]
- Efbemalenograstim alfa vs pegfilgrastim for the management of chemotherapy-induced neutropenia: Results of a Phase III Randomized Noninferiority Trial in Breast Cancer [Acrotech Biopharma]
- Ravulizumab provides durable control of intravascular hemolysis and improves survival in patients with paroxysmal nocturnal hemoglobinuria: long-term follow-up of study 301 and comparisons with patients of the international PNH registry [Alexion and
Astrazeneca Rare Disease]
- Ultra-low PSA response (<0.02 ng/mL) with darolutamide plus ADT and the correlation with outcomes in the ARANOTE study [Bayer]
- Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D [BeOne Medicines Ltd]
- Optimizing post–chimeric antigen receptor (CAR) T cell monitoring: evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience [Bristol Myers Squibb]
- Primary analysis of the Phase 2 IDeate-Lung01 study of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer (ES-SCLC), including intracranial activity in a subgroup with baseline brain metastases (BM) [Daiichi Sankyo, Inc.]
- Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation-negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer [Foundation Medicine]
- Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): [Gilead Sciences, Inc.]
- primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study
- Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non–small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: Phase 3 KEYNOTE-D46/EVOKE-03 study [Gilead Sciences, Inc.]
- Updated results of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma: DREAMM-8 [GSK]
- Impact of dual spleen response and transfusion independence on survival in JAK inhibitor–naive patients with myelofibrosis and anemia treated with momelotinib: a subgroup analysis of SIMPLIFY-1 [GSK]
- IMforte: results from a phase 3 study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line maintenance treatment in patients with extensive-stage small cell lung cancer (ES-SCLC) [Jazz Pharmaceuticals]
- Impact of social risk factors on access to first line treatments among patients with newly diagnosed multiple myeloma in Florida. [Johnson & Johnson]
- Mechanisms of acquired resistance to first-line amivantamab plus lazertinib vs osimertinib: Updated analysis from MARIPOSA [Johnson & Johnson]
- Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study [Menarini-Stemline]
- Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2 [Pfizer]
- Clinical and patient-reported outcomes in C-POST: A phase 3 trial of adjuvant cemiplimab versus placebo for high-risk cutaneous squamous cell carcinoma (CSCC) [Regeneron Pharmaceuticals, Inc]
- Results from VERIFY, a phase 3, double-blind, placebo (PBO)-controlled study of rusfertide for treatment of polycythemia vera (PV) [Takeda]
- Effect of fruquintinib in patients with heavily pretreated metastatic colorectal cancer according to prognostic factors at baseline: Exploratory analysis of FRESCO-2 [Takeda]
Photos
